Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2018-07-25 Interim / Quarterly Rep…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 7 pages 229.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 30 June 2018' and is an ASX announcement. It contains detailed quarterly cash flow statements, including operating, investing, and financing activities, with specific figures for the quarter ended 30 June 2018. The document references compliance with Listing Rule 4.7B, which pertains to quarterly reports for entities listed on the ASX. The content is a comprehensive quarterly financial report with actual financial data and analysis, not merely an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2018
2018-07-25 English
Ceasing to be a substantial holder 2 pages 104.2KB
Regulatory Filings Classification · 95% confidence The document text is extremely short (452 characters) and contains no substantive content, only placeholders for omitted pictures and some unintelligible characters. There is no financial data, no report title, no regulatory references, no mention of fiscal periods, or any other indicators of a specific filing type. Given the lack of content and the presence of only images or placeholders, this document does not represent a full report or announcement. It is best classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2018-05-15 English
NTCELL and Parkinsons trial update 4 pages 211.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 15 May 2018. It reports on the one-year follow-up data from a Phase IIb clinical trial of their product NTCELL for Parkinson's disease, focusing on safety and efficacy results. The content is a clinical trial update and scientific progress announcement rather than a financial report, regulatory filing, or management discussion. It does not contain financial statements, earnings data, or governance information. It is not a report publication announcement since it provides substantive trial results and commentary. The document is best classified as a general regulatory announcement about clinical trial progress and product development, which fits under Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2018-05-14 English
Appendix 4C - quarterly 7 pages 895.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 31 March 2018' and is an ASX announcement. It contains detailed quarterly cash flow statements, including operating, investing, and financing activities, as well as cash balances and estimated cash outflows for the next quarter. The document references compliance with Listing Rule 4.7B, which pertains to quarterly reporting requirements for entities listed on the ASX. The content is a comprehensive quarterly financial report with actual financial data and analysis for a period shorter than a full fiscal year. It is not merely an announcement of a report but the report itself. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2018
2018-04-25 English
LCT Strategy Update 4 pages 310.5KB
Management Reports Classification · 95% confidence The document is titled 'LCT Strategy Update' and dated 11 April 2018. It provides a detailed update on the company's strategic direction, research projects, clinical trials, company restructuring, cash flow, and investor relations. It discusses ongoing and future research initiatives, management appointments, and financial runway but does not contain formal financial statements or comprehensive financial performance data. The document is longer than 5,000 characters and is not a brief announcement or a certification. It is not a full annual or interim report, nor is it a regulatory filing or announcement of a report. The content focuses on management's explanation of business trends, strategy, and outlook, which aligns with the definition of a Management Report (MDA). Therefore, the appropriate classification is Management Reports (MDA).
2018-04-10 English
Half Yearly Report and Accounts 21 pages 1.8MB
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "Half yearly report ended 31 December 2017" and includes detailed financial statements, directors' report, auditor's review report, and consolidated financial statements for the six months ended 31 December 2017. It contains substantive financial data and analysis, including operating results, business review, and financial position. The document is not a brief announcement or a notice of report publication but the actual interim financial report itself. The presence of detailed financial statements and directors' report confirms it is an Interim / Quarterly Report rather than just an announcement or summary. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). H1 2018
2018-02-21 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.